Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab
Sign Up to like & getrecommendations! Published in 2020 at "Osteoporosis International"
DOI: 10.1007/s00198-020-05379-z
Abstract: Romosozumab, an anti-sclerostin antibody, has been approved for prescription in the USA, Europe, Japan, and South Korea to treat patients with osteoporosis who have a high risk of fracture. The Active-Controlled Fracture Study in Postmenopausal… read more here.
Keywords: difference; trial; probability; alendronate ... See more keywords